These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

79 related articles for article (PubMed ID: 1363758)

  • 1. [Comparison of radiometric, immunometric, and immunohistochemical methods for the determination of hormonal receptors and quality control of other prognostic parameters in the characterization of carcinoma of the breast].
    Piffanelli A; Pelizzola D; Giovannini G; Catozzi L; Uccelli L; Barozzi R; Giganti M
    Pathologica; 1992; 84(1094):61-4. PubMed ID: 1363758
    [No Abstract]   [Full Text] [Related]  

  • 2. Simultaneous quantitative analyses of c-erbB-2 protein, epidermal growth factor receptor, cathepsin D, and hormone receptors in breast cancer.
    Iwase H; Itoh Y; Kuzushima T; Yamashita H; Iwata H; Toyama T; Hara Y; Kobayashi S
    Cancer Detect Prev; 1997; 21(1):29-35. PubMed ID: 9043760
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Tumour epidermal growth factor receptor, erbB-2 and cathepsin D in node-negative invasive breast cancer: their impact on the selection of patients for systemic adjuvant therapy.
    Tonkin KS; McKay JW; Stitt LW; Tokmakejian S; Haines DS
    Cancer Prev Control; 1999 Apr; 3(2):131-6. PubMed ID: 10474760
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Prognostic factors in breast cancer patients].
    Roisman I; Peretz T; Reznick AZ; Lifshitz I; Bitterman A; Fares F; Toledano H; Barzilay A; Durst AL
    Harefuah; 1996 May; 130(10):693-9. PubMed ID: 8794662
    [No Abstract]   [Full Text] [Related]  

  • 5. Application of image analysis to the evaluation of cellular prognostic factors in breast carcinoma.
    Bacus SS; Ruby SG
    Pathol Annu; 1993; 28 Pt 1():179-204. PubMed ID: 8093211
    [No Abstract]   [Full Text] [Related]  

  • 6. [Clinical-biological meaning of progesterone receptor status in 118 estrogen receptor positive infiltrating ductal carcinomas of the breast in post-menopausal women].
    Ruibal A; Schneider J; Arias J; del Río MC; Núnez MJ; Tejerina A
    Rev Esp Med Nucl; 2000 Jun; 19(3):244-6. PubMed ID: 11062090
    [No Abstract]   [Full Text] [Related]  

  • 7. Quantitative analysis of c-erbB-2 protein in breast cancer tissue by enzyme immunoassay.
    Narita T; Funahashi H; Satoh Y; Imai T; Takagi H
    Jpn J Clin Oncol; 1994 Apr; 24(2):74-8. PubMed ID: 7908994
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Immunohistochemical localization of metallothionein in human breast cancer in comparison with cathepsin D, stromelysin-1, CD44, extracellular matrix components, P53, Rb, C-erbB-2, EGFR, steroid receptor content and proliferation.
    Ioachim E; Kamina S; Demou A; Kontostolis M; Lolis D; Agnantis NJ
    Anticancer Res; 1999; 19(3A):2133-9. PubMed ID: 10470161
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical, histopathologic, and immunohistochemical features of microglandular adenosis and transition into in situ and invasive carcinoma.
    Khalifeh IM; Albarracin C; Diaz LK; Symmans FW; Edgerton ME; Hwang RF; Sneige N
    Am J Surg Pathol; 2008 Apr; 32(4):544-52. PubMed ID: 18300793
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Value of detection of hormone receptors by biochemical and immunochemical methods in therapeutic decision for breast cancer].
    Goussard J
    Bull Cancer; 1996 Dec; 83(12):1031-6. PubMed ID: 9116370
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Epidermal growth factor receptor-negative tumors are predominantly confined to the subgroup of estradiol receptor-positive human primary breast cancers.
    Koenders PG; Beex LV; Geurts-Moespot A; Heuvel JJ; Kienhuis CB; Benraad TJ
    Cancer Res; 1991 Sep; 51(17):4544-8. PubMed ID: 1873798
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Matrix metalloproteinase expression in human breast cancer: an immunohistochemical study including correlation with cathepsin D, type IV collagen, laminin, fibronectin, EGFR, c-erbB-2 oncoprotein, p53, steroid receptors status and proliferative indices.
    Ioachim EE; Athanassiadou SE; Kamina S; Carassavoglou K; Agnantis NJ
    Anticancer Res; 1998; 18(3A):1665-70. PubMed ID: 9673387
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Immunohistochemical detection of estradiol and progesterone receptors in paraffin sections after treatment with microwaves. Comparison with biochemical assay of receptors in a series of 123 breast cancers with determination of the threshold of optimal positivity].
    Vilain MO; Delobelle-Deroide A; Bloget F; Cabaret V; Peyrat JP; Fournier C; Hecquet B; Fournier J; Vennin P; Bonneterre J
    Ann Pathol; 1997 Apr; 17(2):82-8. PubMed ID: 9221007
    [No Abstract]   [Full Text] [Related]  

  • 14. Evaluation of the prognostic significance of cathepsin D, epidermal growth factor receptor, and c-erbB-2 in early cervical squamous cell carcinoma. An immunohistochemical study.
    Kristensen GB; Holm R; Abeler VM; Tropé CG
    Cancer; 1996 Aug; 78(3):433-40. PubMed ID: 8697388
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Expression of cathepsin D in breast cancer and its clinical and histopathological correlations].
    Ramírez-Ortega MC; Frías-Mendívil M; Delgado-Chávez R; Meneses-García A; Carrillo-Hernández JF; Ramírez-Ugalde MT; Zeichner-Gancz I
    Rev Invest Clin; 1997; 49(5):361-8. PubMed ID: 9527695
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Cathepsin D: an independent prognostic factor in cancer of the breast].
    Romain S; Muracciole X; Varette I; Bressac C; Brandone H; Martin PM
    Bull Cancer; 1990; 77(5):439-47. PubMed ID: 2400813
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Immunohistochemical detection of epidermal growth factor receptor lacks prognostic significance for breast carcinoma.
    Göhring UJ; Ahr A; Scharl A; Weisner V; Neuhaus W; Crombach G; Holt JA
    J Soc Gynecol Investig; 1995; 2(4):653-9. PubMed ID: 9420872
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cathepsin-D and c-erb-B 2 have an additive prognostic value for breast cancer patients.
    Scorilas A; Yotis J; Gouriotis D; Keramopoulos A; Ampela K; Trangas T; Talieri M
    Anticancer Res; 1993; 13(5C):1895-900. PubMed ID: 7903524
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Relationships between epidermal growth factor receptor (EGF-R) and other predictors of prognosis in breast carcinomas. An immunohistochemical study.
    Martinazzi M; Crivelli F; Zampatti C; Martinazzi S
    Pathologica; 1993; 85(1100):637-44. PubMed ID: 8170712
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparison of EGFR, c-erbB-2 product and ras p21 immunohistochemistry as prognostic markers in primary breast cancer.
    Hainsworth PJ; Henderson MA; Stillwell RG; Bennett RC
    Eur J Surg Oncol; 1991 Feb; 17(1):9-15. PubMed ID: 1671658
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.